NCT01070485View on ClinicalTrials.gov

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

January 31, 2012

Conditions

Breast CancerBone Metastases

Interventions

DRUG

Radium-223 chloride (BAY88-8223)

The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).

Trial Locations (4)

1000

Brussels

4000

Liège

0310

Oslo

Unknown

Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY